Literature DB >> 15781961

No go for brain tumors?

Felicia Yu Hsuan Teng1, Bor Luen Tang.   

Abstract

The Nogo gene and its products are well known as adult central nervous system (CNS) myelin inhibitors of neuronal regeneration. We review here experimental findings that might link Nogo to CNS malignancy. These links are founded on two very different modes of cellular action by Nogo isoforms. Acting intracellularly and in conjunction with other molecules, cytoplasmic domains of Nogo might predispose cancer cells to apoptotic susceptibility. On the other hand, extracellular domains of Nogo might inhibit the migration and invasion of CNS tumors. Depending on the physiological context, Nogo isoforms might therefore be antitumorigenic or have tumor-suppressing activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781961     DOI: 10.1385/jmn:25:1:001

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

1.  Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions.

Authors:  Thomas Oertle; Marjan E van der Haar; Christine E Bandtlow; Anna Robeva; Patricia Burfeind; Armin Buss; Andrea B Huber; Marjo Simonen; Lisa Schnell; Christian Brösamle; Klemens Kaupmann; Rüdiger Vallon; Martin E Schwab
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

2.  LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.

Authors:  Sha Mi; Xinhua Lee; Zhaohui Shao; Greg Thill; Benxiu Ji; Jane Relton; Melissa Levesque; Norm Allaire; Steve Perrin; Bryan Sands; Thomas Crowell; Richard L Cate; John M McCoy; R Blake Pepinsky
Journal:  Nat Neurosci       Date:  2004-02-15       Impact factor: 24.884

3.  Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer.

Authors:  Q Li; B Qi; K Oka; M Shimakage; N Yoshioka; H Inoue; A Hakura; K Kodama; E J Stanbridge; M Yutsudo
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

4.  P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp.

Authors:  Kevin C Wang; Jieun A Kim; Rajeev Sivasankaran; Rosalind Segal; Zhigang He
Journal:  Nature       Date:  2002-10-20       Impact factor: 49.962

5.  Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions.

Authors:  Andrea B Huber; Oliver Weinmann; Christian Brösamle; Thomas Oertle; Martin E Schwab
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

6.  Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth.

Authors:  Marco Domeniconi; Zixuan Cao; Timothy Spencer; Rajeev Sivasankaran; Kevin Wang; Elena Nikulina; Noriko Kimura; Hong Cai; Kangwen Deng; Ying Gao; Zhigang He; Marie Filbin
Journal:  Neuron       Date:  2002-07-18       Impact factor: 17.173

7.  Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact.

Authors:  Xingxing Wang; Soo-Jin Chun; Helen Treloar; Timothy Vartanian; Charles A Greer; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

8.  A new role for Nogo as a regulator of vascular remodeling.

Authors:  Lisette Acevedo; Jun Yu; Hediye Erdjument-Bromage; Robert Qing Miao; Ji-Eun Kim; David Fulton; Paul Tempst; Stephen M Strittmatter; William C Sessa
Journal:  Nat Med       Date:  2004-03-21       Impact factor: 53.440

9.  A metalloprotease activity from C6 glioma cells inactivates the myelin-associated neurite growth inhibitors and can be neutralized by antibodies.

Authors:  T Hensel; V R Amberger; M E Schwab
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

10.  Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter.

Authors:  A T Beliën; P A Paganetti; M E Schwab
Journal:  J Cell Biol       Date:  1999-01-25       Impact factor: 10.539

View more
  1 in total

1.  Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.

Authors:  Nan-Xiang Xiong; Hong-Yang Zhao; Fang-Cheng Zhang; Zhu-Qiang He
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.